Cathy Hudson, MD
Cathy Hudson, MD

Cathy Hudson, MD

Assistant Clinical Professor
School of Medicine, Omaha Campus

Academic Appointments


  • Pediatrics


  • Assistant Clinical Professor

Research and Scholarship

Grant Funding Received

  • A safety and immunogenicity study of quadrivalent HPV (Types 6,11,16, 18) L1 Virus-like particle (VLP) Vaccine in preadolescents and adolescents (Protocol 018-00) Merck & Co (Principal Investigator: Meera Varman)
  • A study to evaluate the quadrivalent HPV (Types 6,11,16, 18) L1 Virus like particle (VLP) in redugin the Incidence of HPV 6-, 11-, 16- and 18- related anogenital warts, and the incidence of HPV 6-, 11-, 16- and 18- related genital infection in 16-23 year old men. (Merck V501-020) Principal Investigator: Meera Varman, MD)
  • A phase 3, randomized, active-controlled, observer-blinded trial, to assess the lot consistency, safety, tolerability, and immunogenicity of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy subjects aged >10 to < 19 (IND 13812) {Oriticik B1971009(6108A1-3001)} Pfizer (Principal Investigator: Meera Varman, MD)
  • A phase II Clinical Trial to study the tolerability and immunogenicity of a 2-dose regimen of V503, multivalent Human Papillomavirus (HPV) L1 Virus-like particle (VLP) vaccine administered to preadolescents and adolescents (9-14 years old) with a comparison to young women (16-26 years old) Merck V503-010 (Principal Investigator: Meera Varman, MD)
  • Present A duration of immunity study, to assess persistence of hSBA Response for up to 48 months after completion of vaccination with bivalent rLP2086, Pfizer B1971033 (Principal investigator: Meera Varman MD)
  • A phase III, stratified , randomized, observer blind, controlled, multicenter clinical study to evaluate the safety, immunogenicity and efficacy of an adjuvanted quadrivalent subunit influenza virus vaccine compared to non- adjuvanted comparator influenza vaccine in children >6 to < 72 months of age. V118-05 (Principal Investigator: Meera Varman, MD)